Multiomic study shows antiaging effects of GLP-1RAs
Could GLP-1 receptor agonists (GLP-1RAs), already used in obesity and diabetes, be repurposed as drugs to slow aging? Hong Kong, one of the places in the world with the highest human longevity, is also home to a scientific study on the effects of GLP-1RAs. For the first time, scientists at the Chinese University of Hong […]
Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw
Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate growth in the biologics space. The company is uniquely positioned with interchangeable biosimilar insulins and aims to capitalize on the growing GLP-1 market, bolstered by its acquisition of Viatris’ biosimilars business.
Low Doses of Ozempic-Like Drug Can Counteract Aging in Older Mice, Study Finds
A new study published in the journal Cell Metabolism strongly suggests that low doses of weight loss drugs like Ozempic and Zepbound can counteract aging in middle-aged mice, adding to the growing suspicion that these medications might also increase human longevity. The team of researchers, led by the Chinese University of Hong Kong, set out […]
An Oral GLP-1 Pill Could Change the Future of Diabetes Care
Post Content
Novo Nordisk Alzheimer’s studies may reveal GLP-1 benefits | REUTERS
Studies from Novo Nordisk will give the strongest indication yet of whether blockbuster GLP-1 drugs, a class being used by millions for diabetes and weight loss, can slow progress of Alzheimer’s disease. #News #Reuters #Newsfeed #novonordisk #alzheimers Read the story here: https://reut.rs/48oHZou 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: […]
The Free Market Alone Won’t Cut GLP-1 Prices
Absent tools such as rebate reform, transparent pricing or accelerated biosimilar substitution, true price competition will remain limited.
AI treatment for weight-loss: Artificial Intelligence tools help researchers analyze 1,300 medical conditions, right medicines
Researchers analyzed 14 million doctors’ notes and 15 million clinical data entries from more than 135,000 patients with and without diabetes who each took only one GLP-1 drug.
Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy
People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in their health, such as improved blood sugar, lower blood pressure and weight loss.
Daily pill could offer alternative to weight-loss injections
Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it seems less effective than injectable drugs
Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs
Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.